GlassScriptPhysician profile
John A Gardner
NPI 1770826299
$1,299.87
in general payments reported to CMS, 2019-2025
24 companies · $227 in 2025
The $227 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.49 · 2020: $45.26 · 2021: $277 · 2022: $162 · 2023: $159 · 2024: $337 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $723.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $260.77 | 2023-2025 | |
| Abbott Laboratories | $232.19 | 2019-2024 | Proclaim, Axium |
| Collegium Pharmaceutical, INC. | $93.78 | 2019-2021 | |
| Lundbeck LLC | $87.21 | 2022-2023 | Vyepti |
| Boston Scientific Corporation | $77.56 | 2024-2025 | Intracept |
| Amgen INC. | $74.77 | 2021-2022 | |
| Si-Bone, INC. | $51.59 | 2019-2021 | |
| Allergan, INC. | $48.71 | 2020-2021 | |
| Lilly USA, LLC | $38.51 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.94 | 2020-2022 | |
| Hikma Pharmaceuticals USA | $35.00 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $32.91 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.40 | 2022 | |
| Pfizer INC. | $24.70 | 2024 | |
| Saluda Medical Americas, INC. | $24.50 | 2025 | Evoke |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $23.77 | 2021 | |
| Valinor Pharma, LLC | $23.35 | 2025 | Movantik |
| Pacira Pharmaceuticals Incorporated | $19.42 | 2024 | Exparel |
| Tonix Medicines, INC. | $18.17 | 2025 | Tonmya |
| Indivior INC. | $15.71 | 2025 | Sublocade |
| Scilex Pharmaceuticals INC. | $15.43 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.37 | 2019 | |
| Eagle Pharmaceuticals, INC. | $12.91 | 2023 | |
| Nevro Corp. | $12.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.